Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: A pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population

Clinical Drug Investigation

Volumn 30, Issue 2, 2010, Pages 133-142

  Annemans, L ^a,b   Marbaix, S ^c   Webb, K ^d   Van Gaal, L ^e   Scheen, A ^f  

^a GHENT UNIVERSITY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c PFIZER INC   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; DISEASE SIMULATION; DRUG COST; EMERGENCY CARE; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; BELGIUM; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUGS, GENERIC; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; MODELS, STATISTICAL; PYRROLES; QUALITY-ADJUSTED LIFE YEARS; TRIGLYCERIDES;

EID: 75149139408     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11531910-000000000-00000     Document Type: Article

References (24)

1. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical trial practice: executive summary. The Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2007 Oct; 28 (19): 2375-2414
2. Jönsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002; 45: S5-12
3. Wallemacq C, Van Gaal LF, Scheen AJ. Le coût du diabète de type 2: résumé de l'enquête européenne CODE-2 et analyse de la situation en Belgique. Rev Med Liège 2005; 60 (5-6): 278-284
4. Ryden L, Standl E, Bartnik M, et al., Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136
5. Paquot N, Vandenberghe H, Scheen AJ, et al. Glycaemic and blood pressure control seems harder to improve than lipid control in type 2 diabetic patients: comparison of two surveys over 5 years in Belgium [abstract A-08-953-EASD]. Presented at the European Association for the Study of Diabetes (EASD); 2008 Sep 7-11; Rome
6. Colhoun HM, Betteridge DJ, Durrington PN, et al., on behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): a multi-centre randomized placebo-controlled trial. Lancet 2004; 364: 685-696
7. Raikou M, McGuire A, Colhoun HM, et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007; 50: 733-740
8. Lafuma A, Colin X, Solesse A. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS. Arch CVD Dis 2008; 101: 327-332
9. Ramsey SD, Clarke LD, Roberts CS, et al. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. Pharmacoeconomics 2008; 26 (4): 329-339
10. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001; 101: 671-679
11. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002 Jul; 33 (7): 1776-1781
12. Haffner SM, Letho S, Ronnemma R, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998; 339: 229-234
13. National Institute for Statistics [online]. Available from URL: http://www.statbel.fgov.be [Accessed 2009 Aug 1]
14. Debacker N, Mathieu C, Nobels F, et al. Initiative pour la promotion de la qualité et épidémiologie du diabète sucré IPQED, rapport résultats 2005-2006 [report no. 2007-010]. Institut Scientifique de Santé Publique, Section Epidémiologie [online]. Available from URL: http: //www.iph.fgov. be/epidemio [Accessed 2009 Aug 1]
15. TCT database [online]. Available from URL: http://www. tct.fgov.be [Accessed 2009 Aug 1]
16. Annemans L, Lamotte M, Levy E, et al. Cost-effectiveness analysis of clopidogrel versus aspirin in patients with atherothrombosis based on the CAPRIE trial. J Drug Assessment 2003; 6: 107-120
17. Annemans L, De Backer W, Van Rompay W, et al. Evaluation of the costs of coronary heart disease in Belgium. Podium presentation at ISPOR Third Annual Congress; 1998 May 27-30; Philadelphia (PA)
18. Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a project risk model. Atherosclerosis 1998; 137 (Suppl.): 111-116
19. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006: 86-92
20. INAMI [online]. Available from URL: http://www.inami. be [Accessed 2009 Aug 1]
21. Huang ES, Morgan S, Jin L, et al. The impact of patient p on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care 2006 Feb; 29 (2): 259-264
22. Maddigan SL, Feendy DH, Majumdar SR, et al. Understanding the determinants of health for people with type 2 diabetes. Am J Public Health 2006 Sep; 96 (9): 1649-1655
23. Cleemput I, Van Wilder Ph, Vrijens F, et al. Recommandations pour les évaluations pharmacoéconomiques en Belgique. KCE report 78B, 2008 [online]. Available from URL: http://www.kce.be [Accessed 2009 Aug 1]
24. Beck JR, Pauker SG, Gottlieb JE, et al. A convenient approximation of the life expectancy (the DEALE): II. Use in medical decision-making. Am J Med 1982 Dec; 73 (6): 889-897